N- (2- (triphenylmethyl)thioethyl)- 3- aza- 19- ethyloxycarbonyl- 3- (2- (triphenylmethyl)thioethyl)octadecanoate

10/01/2011 - "The biodistribution and micro-single-photon emission computed tomography/computed tomography image data showed that (188)Re-MN-16ET/Lipiodol was selectively retained at the tumor site, with 11.55±1.44, 13.16±1.46 and 10.67%±0.95% of injected dose/g at 1, 24 and 48 h postinjection, respectively. "
07/01/2013 - "In this study, we further evaluated the therapeutic efficacy of this radiopharmaceutical by measuring tumor response and survival times in rats with liver tumors after intra-hepatic arterial injection of Re-188 MN-16ET lipiodol. "

07/01/2013 - "The p value was 0.0067 between Group 1 and Group 3; 0.04 between Group 1 and Group 2; and 0.034 between Group 2 and Group 3. Re-188 MN-16ET lipiodol has good potential for the treatment of hepatoma."
10/01/2011 - "Twenty-four rats implanted with hepatoma were injected with 3.7 MBq/0.1 ml of (188)Re-MN-16ET/Lipiodol or (188)Re-MN-16ET via transcatheter arterial embolization. "
10/01/2011 - "Synthesis and application of 188Re-MN-16ET/Lipiodol in a hepatocellular carcinoma animal model."
10/01/2011 - "The potential of (188)Re-MN-16ET/Lipiodol for hepatoma therapy was evaluated in a hepatocellular carcinoma animal model of Sprague-Dawley rats implanted with the N1S1 cell line. "
10/01/2011 - "From the animal data, we suggest that (188)Re-MN-16ET/Lipiodol has the potential to be a therapeutic radiopharmaceutical for hepatoma treatment."